International cost-effectiveness analysis of chemoradiotherapy plus pembrolizumab for locally advanced cervical cancer.

ABSTRACT:

Objective

Pembrolizumab administration can improve concurrent chemoradiotherapy (CCRT) efficacy in newly diagnosed, high-risk, locally advanced cervical cancer (LACC). Given the importance of balancing the costs of innovative therapeutics against their efficacy, this study was developed to assess the cost-effectiveness from the perspective of payers in Americas, Europe, and Asia.

Methods

The main survival and other relevant parameters of 1,060 LACC patients from the KEYNOTE-A18 trial were collected to establish a lifetime 3-state Markov model to evaluate the cost and effectiveness of pembrolizumab-CCRT and placebo-CCRT. Primary outcome measures included total cost, life-years (LYs), quality-adjusted LYs (QALYs), incremental cost-effectiveness ratio (ICER), incremental net mo

SUBMITTER: Liu K 

PROVIDER: S-EPMC12636136 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature